Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

TH QUARTER ENDED DECEMBER 31, 2007

Consolidated revenues were $10.2 million for the fourth quarter ended December 31, 2007 compared to $11.9 million for the same quarter in 2006. The decrease in revenues is attributable to lower sales of Impavido(R), as well as active pharmaceutical ingredients to the Company's partners, combined with lower license fees from the Company's partners.

Selling, General and Administrative (SG&A) expenses were $5.1 million for the fourth quarter ended December 31, 2007 compared to $4.2 million for the same quarter in 2006. The increase in SG&A is mainly related to the support of the continuation of a Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH) and the opening of a new operational headquarters in New Jersey.

Consolidated Research & Development (R&D) expenses were $13.6 million for the fourth quarter ended December 31, 2007 compared to $7.9 million for the same quarter in 2006. The increase in R&D expenses relates to the continuation of the Company's Phase 3 program with cetrorelix in BPH.

Consolidated net loss was $13.6 million or $0.26 per basic and diluted share for the fourth quarter ended December 31, 2007 compared to consolidated net earnings of $39.1 million or $0.74 per basic and diluted share for the same quarter in 2006. The increased net loss in the fourth quarter 2007 is related to higher loss from operations of nearly $5.2 million mainly related to increased R&D expenses, as well as to lower income tax recovery of nearly $28.4 million attributable to the recognition of future income tax assets mainly related to the sale of Atrium shares in 2006 and the special distribution of the Company's remaining interest in January 2007, combined with the decrease in net earnings from Atrium's discontinued operations of approximately $16.3 million.

The consolidated cash and short-term investments were $41.4 million as of December 31, 2007.

CONSOLIDATED RESULTS FOR THE FULL
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DIEGO , Sept. 19, 2014 Pfenex ... in the development of high-value and difficult to manufacture ... be presenting at the 21 st Annual NewsMakers ... York . Bertrand Liang , chief executive ... company,s development programs and business strategy on Friday, September ...
(Date:9/19/2014)... Barnhardt Manufacturing Company has ... Organic Cotton . The USDA Certified Biobased Product ... ingredients meets or exceeds levels set by USDA. Biobased ... or in significant part of agricultural, forestry, or marine ... cotton to be immediately identified as a USDA certified ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/19/2014)... 2014 The new , Healthcare and ... available today on PharmaBoardroom.com for free download ... rocked the Spanish economy in 2009, and the austerity measures ... remained pragmatic in times of trouble. "Despite the ... biggest European market, and the general conditions to invest are ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... Wis. - Commercial air service doesn't always ... viewed as more fundamental to enterprise than ever ... potential customers to dismiss the expenses of putting ... of Internet video and mixed-media communication tools. , ...
... a visit to the University of Wisconsin-Madison campus, former ... his name is under attack from critics who don't understand the ... at the annual Kastenmeier Lecture at the UW-Madison Law School ... Bayh-Dole Act , which gave universities the right to patent ...
... back, we took a look at the results of the National ... time, we saw that the Midwest had two states in the top ... top 20 states. I promised to circle back with you to review ... Midwest fared in this ranking. , ,The NIH falls under the ...
Cached Biology Technology:IP video goes where air travel cannot 2IP video goes where air travel cannot 3Landmark patent law under attack, Bayh says 2Landmark patent law under attack, Bayh says 3Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... International Space Station ever starts a "frequent flyers" program, ... Recently the orbiting laboratory has hosted increasing numbers of ... from the space station in April, and another is ... experiment is planned to launch in December. , Fruit ... the world-- and in space. Model organisms can reveal ...
(Date:9/18/2014)... language is unique to humans. "The genetic changes that ... evolution to make this possible are largely unknown, but ... says Wolfgang Enard, Professor of Anthropology and Human Biology ... biological basis of language Enard has now taken an ... undertaken in collaboration with scientists at several universities, including ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University of Texas Medical Branch at Galveston have identified women ... acetate, more commonly known as Depo-Provera or the birth control ... use DMPA will gain weight and will help physicians to ... 5 percent within the first six months of use, called ...
... research shows that training your brain may be just as ... injuries, and suggests a shift from performance-based to prevention-based athletic ... is one of the four major ligaments of the knee, ... well as an economic strain on the medical system. ...
... 2009 Scientists at Burnham Institute for Medical Research (Burnham) ... a major role in promoting programmed cell death (apoptosis), helps ... and invade surrounding tissues. The study was published in the ... team of scientists, led by Kristiina Vuori, M.D., Ph.D., professor ...
Cached Biology News:UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2Knee injuries may start with strain on the brain, not the muscles 2Protein that promotes cancer cell growth identified 2
Purified anti-mouse Tim-1...
Request Info...
Request Info...
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: